Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V505 vs Gardasil in Healthy Women
NCT00520598Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2007
- Primary completion
- May 2011
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of V505 in human papillomavirus infection, sponsored by Merck & Co.. Started Oct 2007; status: completed.
02
Drugs
V505
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00520598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00520598.